Novo Nordisk’s stock is experiencing a steep drop following major clinical setbacks and intensifying competitive pressure in the weight-loss-drug market.
U.S.-listed shares fell over 5% on Monday to a four-year low, around $45, continuing a downward spiral that has seen the company lose nearly half its value since the beginning of 2025.
